These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10449120)

  • 1. Pharmacodynamics of the long-duration response to levodopa in PD.
    Zappia M; Bosco D; Plastino M; Nicoletti G; Branca D; Oliveri RL; Aguglia U; Gambardella A; Quattrone A
    Neurology; 1999 Aug; 53(3):557-60. PubMed ID: 10449120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
    Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
    Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-duration response to L-dopa in the treatment of early PD.
    Zappia M; Oliveri RL; Bosco D; Nicoletti G; Branca D; Caracciolo M; Napoli ID; Gambardella A; Quattrone A
    Neurology; 2000 May; 54(10):1910-5. PubMed ID: 10822428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.
    Anderson E; Nutt J
    Parkinsonism Relat Disord; 2011 Sep; 17(8):587-92. PubMed ID: 21530356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the long-duration response to levodopa in Parkinson's disease.
    Zappia M; Nicoletti A
    J Neurol; 2010 Nov; 257(Suppl 2):S284-7. PubMed ID: 21080190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of long-duration response to levodopa over time in PD: implications for wearing-off.
    Zappia M; Oliveri RL; Montesanti R; Rizzo M; Bosco D; Plastino M; Crescibene L; Bastone L; Aguglia U; Gambardella A; Quattrone A
    Neurology; 1999 Mar; 52(4):763-7. PubMed ID: 10078724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-duration responses to levodopa during the first year of levodopa therapy.
    Nutt JG; Carter JH; Van Houten L; Woodward WR
    Ann Neurol; 1997 Sep; 42(3):349-55. PubMed ID: 9307256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Sciacca G; Mostile G; Disilvestro I; Donzuso G; Nicoletti A; Zappia M
    Mov Disord; 2023 Apr; 38(4):626-635. PubMed ID: 36840442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
    Nutt JG; Carter JH
    Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
    Donzuso G; Sciacca G; Rascunà C; Cicero CE; Mostile G; Nicoletti A; Zappia M
    J Neurol; 2021 Nov; 268(11):4258-4264. PubMed ID: 33864515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
    Davis TL; Brughitta G; Baronti F; Mouradian MM
    Neurology; 1991 May; 41(5):630-3. PubMed ID: 2027476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
    Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS
    Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
    Djaldetti R; Melamed E
    Ann Neurol; 1996 Mar; 39(3):400-4. PubMed ID: 8602763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
    Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.